What clinical features during a heart failure hospitalization make you defer SGLT-2 inhibitor initiation to outpatient follow-up rather than starting in-hospital?

I have witnessed clinical practice evolve considerably over the past few years on this topic, and there is now increasing emphasis and consensus around initiating SGLT-2 inhibitors during a heart failure hospitalization rather than waiting until after discharge. Evidence suggests that benefits begin early, the risk of clinically significant hypotension is generally low, and patients are more likely to receive and continue therapy when it is started before leaving the hospital. Current clinical p...